Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage

British Journal of Haematology

Volumn 73, Issue 3, 1989, Pages 403-409

  Porter, John B ^a   Jaswon, Mervyn S ^a   Huehns, Ernst R ^a   East, Charles A ^b   Hazell, Jonathan W P ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Royal Ear Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE;

ARTICLE; CLINICAL ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON OVERLOAD; MALE; OTOTOXICITY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; DRUG EVALUATION; FEMALE; FERRITIN; HEARING LOSS, SENSORINEURAL; HUMAN; MALE; MIDDLE AGE; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; THALASSEMIA;

EID: 0024310392     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1989.tb07761.x     Document Type: Article

References (26)

1. Desferrioxamine administered intravenously by infusion causes a loss of retinal sensitivity in rabbits anaesthetised with methane
2. Ocular changes in patients undergoing long‐term desferrioxamine treatment
3. Long‐term chelation therapy in thalassaemia major: Effect on liver iron concentration, liver histology and clinical progress
4. Cerebral and ocular toxicity induced by desferrioxamine
5. Visual loss in patient on high‐dose subcutaneous desferrioxamine
6. Ocular toxicity of high‐dose intravenous desferrioxamine
7. Auditory involvement in thalassaemia major
8. Acute deafness and desferrioxamine
9. ENT involvement in thalassaemia major
10. Drug toxicity of the inner ear
11. Proposed international standard of human ferritin assay
12. DTPA in the management of iron overload in thalassaemia
13. Tinnitus in a patient with beta‐thalassaemia intermedia on long‐term treatment with desferrioxamine
14. Auditory brainstem response in paediatric audiology
15. Beneficial effects of transfusing a patient with non‐transfusion dependent thalassaemia major
16. Visual and auditory neurotoxicity in patients receiving subcutaneous defroxamine infusions
17. Ocular and auditory toxicity of long‐term high‐dose subcutaneous desferrioxamine therapy
18. Iron chelation using subcutaneous infusions of diethylene triamine penta‐acetic acid (DTPA)
19. Prevention of iron loading in transfusion‐dependent thalassaemia
20. Transfusion and exchange transfusion in sickle cell anaemia, with particular reference to iron metabolism
21. The toxic effects of desferrioxamine
22. The effects of deferoxamine mesylate and hypoxea on the cochlea
23. Desferrioxamine, ocular toxicity and trace metals
24. Clinical usefulness of iron chelating agents
25. Auditory neurotoxicity in patients receiving subcutaneous desferricxamine treatment and the use of calcium diethylene triamine penta acetic acid (DTPA) as an alternative chelator
26. Deferoxamine: eye and ear damage threat